

INTENDED USE

The DRG EBV-VCA IgM ELISA test system is an enzyme-linked immunosorbent assay (ELISA) designed for the qualitative detection of IgM class antibodies to Epstein-Barr Virus viral capsid antigen (EBV-VCA) in human serum. The test system is intended to be used for the diagnosis of EBV-associated infectious mononucleosis when used in conjunction with other EBV serologies.

SUMMARY AND EXPLANATION

Epstein-Barr Virus (EBV) is a ubiquitous human virus which causes infectious mononucleosis (IM), a self limiting lymphoproliferative disease (1). By adulthood virtually everyone has been infected and has developed immunity to the virus. In underdeveloped countries, seroconversion to the virus takes place in early childhood and is usually asymptomatic (2). In more affluent countries, primary EBV infections are often delayed until adolescence or later, and manifest as IM in about 50% of this age group (3-5).

Following seroconversion, whether symptomatic or not, EBV establishes a chronic, latent infection in B lymphocytes which probably lasts for life (6). EBV replicates in oropharyngeal epithelial cells and is present in the saliva of most patients with IM (7). Also, 10-20% of healthy persons who are EBV antibody positive shed the virus in their oral secretions (6-8). Reactivation of the latent viral carrier state, as evidenced by increased rates of virus shedding, is enhanced by immunosuppression, pregnancy, malnutrition, or disease (8,9). Chronic EBV infections, whether latent or active, are rarely associated with disease. However, EBV has been implicated at least as a contributing factor in the etiology of nasopharyngeal carcinoma, Burkitt's lymphoma, and lymphomas in immunodeficient patients (4,8).

The Paul-Bunnell-Davidsohn test for heterophile antibody is highly specific for IM (10). However, 10-15% of adults and higher percentages of children and infants with primary EBV infections do not develop heterophile antibodies (11). EBV-specific serological tests are needed to differentiate primary EBV infections that are heterophile negative from mononucleosis-like illnesses caused by other agents such as cytomegalovirus, adenovirus, and *Toxoplasma gondii* (4). Antibody titers to specific EBV antigens correlate with different stages of IM (4, 10-12). Both IgM and IgG antibodies to the viral capsid antigen (VCA) peak 3 to 4 weeks after primary EBV infection. IgM anti-VCA decline rapidly and is usually undetectable after 12 weeks. IgG anti-VCA titers decline slowly after peaking but last indefinitely. Antibodies to EBV nuclear antigen (EBNA) develop from 1 month to 6 months after infection and, like anti-VCA, persist indefinitely (11,12). Antibodies to EBNA indicate that the infection was not recent (11).

EBV early antigens (EA) consist of two components; diffuse (D), and restricted (R). The terms D and R reflect the different patterns of immunofluorescence staining exhibited by the two components (13,14). Antibodies to EA appear transiently for up to three months during the acute phase of IM in 85% of patients (15,16). The antibody response to EA in IM patients is usually to the D component, whereas silent seroconversion to EBV in children produces antibodies to the R component (5,11). A definitive diagnosis of primary EBV infection can be made with 95% of acute phase sera based on the detection of antibodies to VCA, EBNA, and EA (12).

High levels of anti-VCA together with anti-EBNA and anti-EA-R are associated with reactivation of the latent viral carrier state (16,17). High levels of IgG anti-VCA are found in sera of patients with immunodeficiencies (6,18), recurrent parotitis (19), multiple sclerosis (20), and nasopharyngeal carcinoma (21); as well as immunosuppressed patients (8, 22), pregnant women (23), and persons of advanced age (17).

Screening for the presence of antibodies to VCA and related antigens of EBV can provide important information for the diagnosis of EBV infection. Indirect immunofluorescence has been the serologic method most commonly used to detect antibodies to EBV antigens (11). However, the ELISA procedure, first described by Engvall and Penman (24,25), may be a sensitive and reliable method for detection of antibodies to EBV antigens (26,27). The ELISA procedure allows an objective determination of antibody status to be made on a single dilution of the test specimen and is suitable for screening large numbers of patient samples.

PRINCIPLE OF THE ELISA ASSAY

The DRG EBV-IgM ELISA test is designed to detect IgM class antibodies to EBV IgM in human sera. Wells of plastic microwell strips are sensitized by passive absorption with EBV antigen. The test procedure involves three incubation steps:

1. Test sera are diluted with the Sample Diluent provided. The Sample Diluent contains antihuman IgG that precipitates and removes IgG and rheumatoid factor from the sample leaving IgM free to react with the immobilized antigen. During sample incubation any antigen specific IgM antibody in the sample will bind to the immobilized antigen. The plate is washed to remove unbound antibody and other serum components.
2. Peroxidase Conjugated goat anti-human IgM (μ chain specific) is added to the wells and the plate is incubated. The Conjugate will react with IgM antibody immobilized on the solid phase in step 1. The wells are washed to remove unbound Conjugate.
3. The microwells containing immobilized peroxidase Conjugate are incubated with peroxidase Substrate Solution. Hydrolysis of the Substrate by peroxidase produces a color change. After a period of time the reaction is stopped and the color intensity of the solution is measured photometrically. The color intensity of the solution depends upon the antibody concentration in the original test sample.

MATERIALS PROVIDED

Each kit contains the following components in sufficient quantities to perform the number of tests indicated on packaging label.

1. **Plate.** 96 wells configured in twelve 1x8-well strips coated with affinity-purified 125kD capsid peptide purified from induced P3-HR1 cells. The strips are packaged in a strip holder and sealed in an envelope with desiccant.
2. **Conjugate.** Conjugated (horseradish peroxidase) goat anti-human IgM (μ chain specific). Ready to use. One, 15 mL vial with a white cap. Preservative added.
3. **Positive Control** (Human Serum). One, 0.35 mL vial with a red cap. Preservative added.
4. **Calibrator** (Human Serum). One, 0.5 mL vial with a blue cap. Preservative added.
5. **Negative Control** (Human Serum). One, 0.35 mL vial with a green cap. Preservative added.
6. **Sample diluent.** One 30 mL bottle (blue cap) containing Tween-20, bovine serum albumin, phosphate-buffered-saline, and goat anti-human IgG (γ -chain specific), (pH 7.2 ± 0.2). Purple solution; ready to use. Note: Shake Well Before Use. Preservative added.
7. **TMB:** One 15 mL amber bottle (amber cap) containing 3,3',5,5'-tetramethylbenzidine (TMB). Ready to use. Contains DMSO $\leq 15\%$ (w).
8. **Stop solution:** One 15 mL bottle
9. (red cap) containing 1 M H_2SO_4 , 0.7M HCl. Ready to use.
10. Wash buffer concentrate (10X): dilute 1 part concentrate + 9 parts deionized or distilled water. One 100 mL bottle (clear cap) containing a 10X concentrated phosphate-buffered-saline and Tween-20 solution (blue solution). Contains preservative. **NOTE:** 1X solution will have a pH of 7.2 ± 0.2 .

PRECAUTIONS

1. For *In Vitro* Diagnostic Use.
2. Normal precautions exercised in handling laboratory reagents should be followed. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the ELISA plate do not contain viable organisms. However, the strips should be considered **POTENTIALLY BIOHAZARDOUS MATERIALS** and handled accordingly.
4. The human serum controls are **POTENTIALLY BIOHAZARDOUS MATERIALS**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, these products should be handled at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories": current edition; and OSHA's Standard for Bloodborne Pathogens (33).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20-25°C) before starting the assay.** Return unused reagents to refrigerated temperature immediately after use.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual wash solution; (e.g., by blotting or aspiration) before adding Conjugate or Substrate. Do not allow the wells to dry out between incubations.
7. The human serum controls, Sample Diluent, Conjugate, and Wash Buffer concentrate contain a preservative (thimerosal, 0.04% (w/v)) which may be toxic if ingested.
8. The Stop Solution is TOXIC. Causes burns. Toxic by inhalation, in contact with skin and if swallowed. In case of accident or if you feel unwell, seek medical advice immediately.
9. The TMB Solution is HARMFUL. Irritating to eyes, respiratory system and skin.
10. The Wash Buffer concentrate is an IRRITANT. Irritating to eyes, respiratory system and skin.
11. Wipe bottom of plate free of residual liquid and/or fingerprints that can alter optical density (OD) readings.
12. Dilution or adulteration of these reagents may generate erroneous results.
13. Reagents from other sources or manufacturers should not be used.
14. TMB Solution should be colorless, very pale yellow, very pale green, or very pale blue when used. Contamination of the TMB with conjugate or other oxidants will cause the solution to change color prematurely. Do not use the TMB if it is noticeably blue in color.
15. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
16. Avoid microbial contamination of reagents. Incorrect results may occur.
17. Cross contamination of reagents and/or samples could cause erroneous results.
18. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
19. Avoid splashing or generation of aerosols.
20. Do not expose reagents to strong light during storage or incubation.
21. Allowing the microwell strips and holder to equilibrate to room temperature prior to opening the protective envelope will protect the wells from condensation.
22. Wash solution should be collected in a disposal basin. Treat the waste solution with 10% household bleach (0.5% sodium hypochlorite). Avoid exposure of reagents to bleach fumes.
23. Caution: Liquid waste at acid pH should be neutralized before adding to bleach solution.
24. Do not use ELISA plate if the indicator strip on the desiccant pouch has turned from blue to pink.



Revised 27 Dec. 2006 (Vers. 1.1)



25. Do not allow the conjugate to come in contact with containers or instruments that may have previously contained a solution utilizing sodium azide as a preservative. Residual amounts of sodium azide may destroy the conjugate's enzymatic activity.
26. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (sodium hypochlorite) may destroy the biological activity of many of the reactive reagents within this kit.

MATERIALS REQUIRED BUT NOT PROVIDED:

- ELISA microwell reader capable of reading at a wavelength of 450nm.
- Pipettes capable of accurately delivering 10 to 200µL.
- Multichannel pipette capable of accurately delivering (50-200µL)
- Reagent reservoirs for multichannel pipettes.
- Wash bottle or microwell washing system.
- Distilled or deionized water.
- One liter graduated cylinder.
- Serological pipettes.
- Disposable pipette tips.
- Paper towels.
- Laboratory timer to monitor incubation steps.
- Disposal basin and disinfectant, (example: 10% household bleach, 0.5% sodium hypochlorite.)

STORAGE CONDITIONS

1. Store the unopened kit between 2° and 8°C.
2. **Coated microwell strips:** Store between 2° and 8°C. Extra strips should be immediately resealed with desiccant and returned to proper storage. Strips are stable for 60 days after the envelope has been opened and properly resealed and the indicator strip on the desiccant pouch remains blue.
3. **Conjugate:** Store between 2° and 8°C. DO NOT FREEZE.
4. **Calibrator, Positive Control and Negative Control:** Store between 2° and 8°C.
5. **TMB:** Store between 2° and 8°C.
6. **Wash Buffer concentrate (10X):** Store between 2° and 25°C. Diluted wash buffer (1X) is stable at room temperature (20° to 25° C) for up to 7 days or for 30 days between 2° and 8°C.
7. **Sample Diluent:** Store between 2° and 8°C.
8. **Stop Solution:** Store between 2° and 25°C.

SPECIMEN COLLECTION

1. It is recommended that specimen collection be carried out in accordance with NCCLS document M29: Protection of Laboratory Workers from Infectious Disease.
2. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, all blood derivatives should be considered potentially infectious.
3. Only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures should be used in this assay (28, 29). No anticoagulants or preservatives should be added. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.

4. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2° and 8°C for no longer than 48 hours. If delay in testing is anticipated, store test sera at -20°C or lower. Avoid multiple freeze/thaw cycles that may cause loss of antibody activity and give erroneous results.

GENERAL PROCEDURE

1. Remove the individual components from storage and allow them to warm to room temperature (20-25°C).
2. Determine the number of microwells needed. Allow six Control/Calibrator determinations (one Blank, one Negative Control, three Calibrators and one Positive Control) per run. A Reagent Blank should be run on each assay. Check software and reader requirements for the correct Controls/Calibrator configurations. Return unused strips to the resealable pouch with desiccant, seal, and return to storage between 2° and 8°C.

EXAMPLE PLATE SET-UP		
	1	2
A	Blank	Patient 3
B	Neg. Control	Patient 4
C	Calibrator	Etc.
D	Calibrator	
E	Calibrator	
F	Pos. Control	
G	Patient 1	
H	Patient 2	

3. Prepare a 1:21 dilution (e.g.: 10µL serum + 200µL of Sample Diluent. NOTE: Shake Well Before Use) of the Negative Control, Calibrator, Positive Control, and each patient serum.
4. To individual wells, add 100µL of each diluted control, calibrator and sample. Ensure that the samples are properly mixed. Use a different pipette tip for each sample.
5. Add 100 µL of Sample Diluent to well A1 as a reagent blank. Check software and reader requirements for the correct reagent blank well configuration.
6. Incubate the plate at room temperature (20-25°C) for 25 ± 5 minutes.
7. Wash the microwell strips 5X.

A. Manual Wash Procedure:

- a) Vigorously shake out the liquid from the wells.
- b) Fill each microwell with Wash Buffer. Make sure no air bubbles are trapped in the wells.
- c) Repeat steps a. and b. for a total of 5 washes.
- d) Shake out the wash solution from all the wells. Invert the plate over a paper towel and tap firmly to remove any residual wash solution from the wells. Visually inspect the plate to ensure that no residual wash solution remains. Collect wash solution in a disposable basin and treat with 0.5% sodium hypochlorite (bleach) at the end of the days run.

B. Automated Wash Procedure:

If using an automated microwell wash system, set the dispensing volume to 300-350JL/L/well. Set the wash cycle for 5 washes with no delay between washes. If necessary, the microwell plate may be removed from the washer, inverted over a paper towel and tapped firmly to remove any residual wash solution from the microwells.

8. Add 100 µL of the Conjugate to each well, including reagent blank well, at the same rate and in the same order as the specimens were added.
9. Incubate the plate at room temperature (20-25°C) for 25 ± 5 minutes
10. Wash the microwells by following the procedure as described in step 7.
11. Add 100µL of TMB to each well, including reagent blank well, at the same rate and in the same order as the specimens were added.
12. Incubate the plate at room temperature (20-25°C) for 10 to 15 minutes.
13. Stop the reaction by adding 50µL of Stop Solution to each well, including reagent blank well, at the same rate and in the same order as the TMB was added. Positive samples will turn from blue to yellow. After adding the Stop Solution, tap the plate several times to ensure that the samples are thoroughly mixed.
14. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the reagent blank. The plate should be read within 30 minutes after the addition of the Stop Solution.

QUALITY CONTROL

1. Each time the assay is run the Calibrator must be run in triplicate. A reagent blank, Negative Control, and Positive Control must also be included in each assay.
2. Calculate the mean of the three Calibrator wells. If any of the three values differ by more than 15% from the mean, discard that value and calculate the mean using the remaining two wells.
3. The mean OD value for the Calibrator and the OD values for the Positive and Negative Controls should fall within the following ranges:

	<u>OD Range</u>
Negative Control	≤ 0.250
Calibrator	≥ 0.300
Positive Control	≥ 0.500

- a) The OD of the Negative Control divided by the mean OD of the Calibrator should be ≤ 0.9 .
 - b) The OD of the Positive Control divided by the mean OD of the Calibrator should be ≥ 1.25 .
 - c) If the above conditions are not met the test should be considered invalid and should be repeated.
4. The Positive Control and Negative Control are intended to monitor for substantial reagent failure and will not ensure precision at the assay cut-off.
 5. Additional controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.
 6. Refer to NCCLS document C24: Statistical Quality Control for Quantitative Measurements for guidance on appropriate QC practices.

INTERPRETATION OF RESULTS A. Calculations:

1. Correction Factor

A cutoff OD value for positive samples has been determined by the manufacturer and correlated to the Calibrator. The correction factor (CF) will allow you to determine the cutoff value for positive samples and to correct for slight day-to-day variations in test results. The correction factor is determined for each lot of kit components and is printed on the Component List located in the kit box.

2. Cutoff OD Value

To obtain the cutoff OD value, multiply the CF by the mean OD of the Calibrator determined above.

(CF x mean OD of Calibrator = cutoff OD value)

3. Index Values or OD Ratios

Calculate the Index Value or OD Ratio for each specimen by dividing its OD value by the cutoff OD from step 2.

Example:

Mean OD of Calibrator	=	0.793
Correction Factor (CF)	=	0.25
Cut off OD	=	$0.793 \times 0.25 = 0.198$
Unknown Specimen OD	=	0.432
Specimen Index Value or OD Ratio	=	$0.432 / 0.198 = 2.18$

B. Interpretations:

Index Values or OD ratios are interpreted as follows:

	<u>Index Value or OD Ratio</u>
Negative Specimens	≤ 0.90
Equivocal Specimens	0.91 to 1.09
Positive Specimens	≥ 1.10


1. An OD ratio ≤ 0.90 indicates no detectable IgM antibody to EBV-VCA. A negative result indicates no current infection with EBV, and should be reported as non-reactive for EBV-VCA IgM antibody. Such individuals are presumed to be susceptible to primary infection.
2. An OD ratio ≥ 1.10 is positive for IgM antibody to EBV-VCA. A positive test result indicates a current or reactivated infection with EBV, and should be reported as reactive for EBV-VCA IgM antibody.
3. Specimens with OD ratio values in the equivocal range (0.91-1.09) should be retested. Specimens that remain equivocal after repeat testing should be tested by an alternate serologic procedure, such as the DRG indirect fluorescent antibody (IFA) test procedure. Additionally, specimens which remain equivocal after repeat testing should be re-evaluated by drawing another sample one to three weeks later.
4. The numeric value of the final result above the cutoff is not indicative of the amount of anti-EBV-VCA IgM antibody present.

LIMITATIONS OF THE ASSAY

1. Most (80%) of IM individuals have peak anti-VGA IgM titers before they consult a physician (4). Therefore, testing paired acute and convalescent sera for significant changes in antibody levels is not useful in most patients with IM (4).
2. The antibody titer of a single serum specimen should not be used to determine recent infection. Test results for anti-VGA should be interpreted in conjunction with the clinical evaluation and results of antibody tests for other EBV antigens, i.e., EBNA, EA, and IgG-VCA.
3. The lack of detectable IgM antibodies does not exclude current EBV infection. The sample may have been collected before development of demonstrable antibody or after the antibody level is no longer detectable.
4. Test results of specimens from immunosuppressed patients may be difficult to interpret.
5. Specific IgM antibodies are usually detected in patients with recent primary infection, but may be found in patients with reactivated or secondary infections, and they are sometimes found in patients with no other detectable evidence of recent infection.
6. The anti-IgG absorbent has been shown to functionally remove ≥ 13.9 mg/mL IgG from human serum. Normal adult IgG levels may range from 8 to 16 mg/mL (32). Patients with an IgG level exceeding 14 mg/mL may require additional treatment to neutralize all IgG.
7. Performance characteristics of this device have not been established with EBV-associated disease other than infectious mononucleosis.
8. Test results should be evaluated in relation to patient symptoms, clinical history, and other laboratory findings to establish a diagnosis.

EXPECTED VALUES

The presence of EBV-VCA-IgM antibodies as determined by the ELISA method is highly suggestive of acute EBV infection since such antibodies are found early on in the illness in approximately 90% of cases and are not usually present in the general population (31). To demonstrate this, the frequency of IgM antibody to EBV-VCA was evaluated using 74 normal blood donor specimens from southeastern United States. Of the 74 specimens, three (3) were reactive (4.0%), and seventy one (71) were non-reactive (96.0%). A frequency distribution of the actual results appears below:



PERFORMANCE CHARACTERISTICS**Off-Site Clinical Study:**

Clinical studies were performed to demonstrate the clinical efficacy of the DRG International, Inc. EBV-VCA IgM ELISA test system as an aid in the diagnosis of EBV-associated infectious mononucleosis. The performance of the DRG EBV-VCA IgM ELISA was evaluated in a two site clinical investigation. Site one was an independent laboratory located in northeastern U.S. Site two was a commercial serum/serum component vendor located in southeastern U.S.

Briefly, there were a total of 305 specimens tested; 158 at site one, and 147 at site two. Specimens tested at site one included 119 samples which were sent to a reference laboratory for normal EBV serology, 19 specimens previously characterized as EBV negative, and 20 specimens which had been previously characterized as EBV-VCA IgM positive. Specimens tested at site two included 100 specimens which were to be tested for routine EBV serology, 27 specimens which had been previously characterized as VCA IgM positive, and 20 which had been previously characterized as VCA IgM negative. Serologies performed at each site included: Heterophile, EBV-VCA IgG, EBNA, and the EBV-VCA IgM ELISA test.

The criteria for determining assay specificity and sensitivity was as follows: All clinical specimens were classified as to the stage of EBV infection and therefore their probable IgM antibody status based primarily upon their profile with respect to the Heterophile and EBNA results. Specifically, there were four such profiles: (1) Heterophile negative, EBNA positive, (2) Heterophile negative, EBNA negative, (3) Heterophile positive, EBNA negative, and (4) Heterophile positive, EBNA positive. The suspected EBV-VCA IgM serology's of these four profiles, along with the results of this study have been summarized in Tables 1 through 3 below:

**Table 1. Summary of DRG EBV-VCA IgM ELISA Test System.
Clinical Site Number 1**

Heterophile/ EBNA Profile	Stage/IgM Activity	Positive	Negative	Equivocal^a	TOTAL
Heterophile-, EBNA + 96/102 (94%), VCA IgG Positive 0/102 (0%). VCA IgG Equivocal 6/102 (6%), VCA IgG Negative	Past Infection IgM Negative	9	90	3	102
Heterophile -, EBNA -2/33 (6%), VCA IgG Positive 3/33 (9%). VCA IgG Equivocal 28/33 (85%), VCA IgG Negative	Never Infected IgM Negative	0	33	0	33
Heterophile+, EBNA -8/21 (38%), VCA IgG Positive 5/21 (24%), VCA IgG Equivocal 8/21 (38%), VCA IgG Negative	Acute Infection IgM Positive	19	1	1	21
Heterophile +, EBNA + 1/2 (50%), VCA IgG Positive 1/2 (50%), VCA IgG Equivocal 0/2 (0%), VCA IgG Negative	Reactivation IgM Positive	1	1	0	2

^a Equivocal specimens were retested according to the package insert. Specimens which were repeatedly equivocal or not retested due to insufficient volume appear in this column. These remaining equivocal specimens were not used in any calculations for sensitivity or specificity. Of the 158 specimens tested at site 1, there were initially 11 equivocal samples. Seven repeated as negative, three repeated as equivocal, and one was not repeated due to insufficient volume.

Assay Specificity: 123/132 = 93.2% (88.9% to 97.5%)^b

Assay Sensitivity: 20/22 = 90.9% (70.8% to 98.9%)^c

Percent Agreement: 143/154 = 92.9% (88.8% to 96.9%)^b

^b Expressed as a 95% confidence interval calculated using the normal method.

^c Expressed as a 95% confidence interval calculated using the exact method.

**Table 2. Summary of DRG EBV-VCA IgM ELISA Test System.
Clinical Site Number 2**

Heterophile/EBNA Profile	Stage/IgM Activity	Positive	Negative	Equivocal ^a	TOTAL
Heterophile-, EBNA + 65/72 (90.3%) VCA IgG Positive 1/72 (1.4%), VCA IgG Equivocal 6/72 (8.3%) VCA IgG Negative	Past Infection IgM Negative	13	55	4	72
Heterophile -, EBNA – 4/38 (10%) VCA IgG Positive 1/38 (3%) VCA IgG Equivocal 33/38 (87%) VCA IgG Negative	Never Infected IgM Negative	7	31	0	38
Heterophile +, EBNA – 5/26 (19%). VCA IgG Positive 1/26 (4%), VCA IgG Equivocal 20/26 (77%) VCA IgG Negative	Acute Infection IgM Positive	25	1	0	26
Heterophile +, EBNA + 6/11 (55%) VCA IgG Positive 0/11 (0%) VCA IgG Equivocal 5/11 (45%) VCA IgG Negative	Reactivation IgM Positive	11	0	0	11

^a Equivocal specimens were retested according to the package insert. Specimens which were repeatedly equivocal, or not retested due to insufficient volume appear in this column. These remaining equivocal specimens were not used in any calculations for sensitivity or specificity. Of the 147 specimens tested at site 2, there were initially seven (7) equivocal samples. One repeated as negative, two repeated as positive, and four were not repeated due to insufficient volume.

Assay Specificity: 86/106 = 81.1% (73.7% to 88.6%) ^b

Assay Sensitivity: 36/37 = 97.3% (85.8% to 99.9%) ^c

Percent Agreement: 122/143 = 85.3% (79.5% to 91.1%) ^b

^b Expressed as a 95% confidence interval calculated using the normal method.

^c Expressed as a 95% confidence interval calculated using the exact method.

**Table 3. Summary of DRG, EBV-VCA IgM ELISA Test System.
Clinical Sites 1 & 2 Combined**

Heterophile/EBNA Profile	Stage/IgM Activity	Positive	Negative	Equivocal ^a	TOTAL
Heterophile-, EBNA + 161/174 (92.5%) VCA IgG Positive 1/174 (0.6%), VCA IgG Equivocal 12/174(6.9%), VCA IgG Negative	Past Infection IgM Negative	22	145	7	174
Heterophile-, EBNA – 6/71 (8.4%), VCA IgG Positive 4/71 (5.6%). VCA IgG Equivocal 61/71 (85.9%), VCA IgG Negative	Never Infected IgM Negative	7	64	0	71
Heterophile+, EBNA- 13/47 (27.7%), VCA IgG Positive 6/47 (12.8%), VCA IgG Equivocal 28/47 (59.6%), VCA IgG Negative	Acute Infection IgM Positive	44	2	1	47
Heterophile +, EBNA + 7/13 (53.8%). VCA IgG Positive 1/13 (7.7%). VCA IgG Equivocal 5/13 (38.5%), VCA IgG Negative	Reactivation IgM Positive	12	1	0	13

^a Equivocal specimens were retested according to the package insert. Specimens which were repeatedly equivocal, or not retested due to insufficient volume appear in this column. These remaining equivocal specimens were not used in any calculations for sensitivity or specificity.

Assay Specificity: 209/238 = 87.8% (83.7% to 92.0%)^b

Assay Sensitivity: 44/46 = 95.6% (85.2% to 99.5%)^c

Percent Agreement: 253/284 = 89.1% (85.5% to 92.7%)^b

^b Expressed as a 95% confidence interval calculated using the normal method.

^c Expressed as a 95% confidence interval calculated using the exact method.

REPRODUCIBILITY

Reproducibility studies were conducted by both clinical sites as well as at DRG International, Inc. Briefly, six specimens were tested; three strong positive specimens, two moderately positive specimens (close to the cutoff), and one negative specimen. Each specimen was tested in triplicate each day, for a total of three days. The resulting data was used to calculate both intra and inter-assay reproducibility. This has been summarized in Table 4 below:

Intra-Assay Reproducibility Summary:

Sample	Site	Mean Ratios:			Standard Deviation:			Percent CV:			Inter-Assay		
		Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	Mean	Std.	% CV
VM1	1	3.62	3.71	3.49	0.05	0.05	0.02	1.4	1.3	0.6	3.61	0.10	2.8
	2	3.75	3.29	2.98	0.15	0.18	0.59	4.0	5.6	19.9	3.34	0.43	14.6
	3	2.90	2.78	3.13	0.21	0.15	0.23	7.2	5.3	7.4	2.93	0.25	8.4
VMS	1	1.19	1.12	1.09	0.08	0.05	0.05	6.6	4.2	5.0	1.13	0.08	6.7
	2	1.23	1.03	1.06	0.16	0.11	0.10	13.0	11.1	9.2	1.11	0.16	14.0
	3	1.00	0.90	1.00	0.24	0.06	0.26	24.0	6.7	25.5	1.00	0.21	21.5
VM5	1	3.9	4.31	3.64	0.03	0.05	0.04	0.9	1.2	1.2	3.96	0.28	7.0
	2	3.6	3.75	4.19	0.12	0.51	0.14	3.3	13.5	3.4	2.87	0.38	9.9
	3	3.7	3.43	3.47	0.10	0.09	0.16	2.6	2.7	4.5	3.55	0.19	5.4
VM6	1	2.34	2.38	2.23	0.07	0.10	0.01	3.0	4.3	0.6	2.32	0.10	4.2
	2	2.13	2.16	2.50	0.16	0.01	0.08	7.6	0.4	3.3	2.30	0.20	8.7
	3	1.87	1.86	1.82	0.07	0.04	0.12	3.6	2.2	6.4	1.85	0.08	4.5
VM7	1	1.27	1.24	1.20	0.02	0.03	0.03	1.7	2.7	2.6	1.24	0.04	3.2
	2	0.98	1.10	1.30	0.03	0.04	0.05	3.0	4.2	4.0	1.10	0.15	13.4
	3	0.93	0.92	0.91	0.03	0.03	0.09	2.9	2.8	10.1	0.92	0.06	6.2
VM10	1	0.03	0.02	0.03	0.06	0.03	0.03	25.7	14.3	17.1	0.02	0.05	22.9
	2	0.09	0.10	0.12	0.02	0.05	0.01	18.2	54.9	10.7	0.10	0.03	33.8
	3	0.05	0.09	0.07	0.01	0.03	0.02	30.1	27.2	23.3	0.07	0.03	39.3

Interference/Cross Reactivity:

1. Effect of Rheumatoid Factor (RF):

Experimentation was conducted to demonstrate the effectiveness of the diluent at removing potentially interfering RF antibodies. Briefly, twelve specimens which were RF positive and EBV-VCA IgG positive were tested with and without the anti-IgG absorbent included in the EBV-VCA IgM ELISA kit. The results of this study are shown in Table 5.

2. Effective Removal of Competing IgG Antibody:

Specimens which were positive for IgG antibody and IgM antibody to EBV-VCA were tested with and without treatment to demonstrate the effectiveness of the diluent in removing IgG. The results of the study have been summarized in Table 6.

3. Cross Reactivity with Anti-viral IgM Antibodies:

Samples negative for EBV-VCA IgM antibody and positive for IgM antibodies to various viruses such as CMV, Herpes, and Rubella were tested on the DRG, EBV-VCA IgM ELISA test system. One specimen with anti-HSV-1/2 IgM antibody produced an equivocal result. All of the remaining samples were negative. The results of this study have been summarized in Table 7.

**Table 5: Effect of Diluent on RF Positive,
EBV-VCA IgG Positive and EBV-VCA IgM Negative Specimens.
DRG EBV-VCA IgM Result (Ratio)**

Sample ID	With Kit Diluent		Diluent without Anti-IgG		RF Result ^a
NA1	0.209	Neg.	0.686	Neg.	0.96
NA4	0.040	Neg.	0.102	Neg.	2.1
NB6	0.109	Neg.	0.259	Neg.	1.7
NC6	0.185	Neg.	0.487	Neg.	1.5
ND3	0.178	Neg.	0.425	Neg.	1.5
ND7	0.145	Neg.	0.360	Neg.	1.3
NF4	0.280	Neg.	0.079	Neg.	0.82
S69	0.120	Neg.	0.240	Neg.	2.5
CBB2	0.132	Neg.	7.871	Pos.	3.1
CBB11	0.184	Neg.	8.446	Pos.	3.1
CBB19	0.899	Neg.	2.262	Pos.	2.7
CBB15	0.302	Neg.	6.235	Pos.	3.1

^a RF-IgM result determined using a commercial RF ELISA test kit

Interpretation: < 0.80 = Negative
 0.80 - 0.99 = Equivocal
 ≥1.00= Positive

**Table 6. Effect of Diluent on EBV-VCA IgG Positive Specimens;
Functional Removal of IgG Antibody**

DRG EBV-VCA IgG Optical Density (450nm)

Sample ID	With Kit Diluent	Diluent without Anti-IgG
VM1	0.010	0.422
VM2	0.012	0.279
VM5	0.019	0.194
VM6	0.014	0.249
15287	0.027	0.335
15288	0.000	0.255
10847	0.030	0.294

NOTE:

Human serum samples (n=7) w'rth total IgG concentrations ranging from 4.5 to ≥ 13.9 mg/mL were diluted using the diluent according to the directions within this insert. Following treatment, IgG was not detected in any of the specimens. IgG concentrations were determined using a commercial, quantitative radial immunodiffusion detection test system.

**Table 7. DRG International, Inc. Results of Crossreactivity Testing
IgM Reactivity^a**

Sample ID	DRG EBV-VCA IgM Result (Ratio)	Viral Marker	Result (Ratio)
CMV-3	0.053	CMV IgM	1.150
CMV-4	0.058	CMV IgM	1.497
CMV-7	0.515	CMV IgM	1.261
CMV-10	0.074	CMV IgM	1.422
CMV-13	0.047	CMV IgM	1.532
CMV-14	0.042	CMV IgM	0.781
CMV-18	0.536	CMV IgM	7.576
RUB-1	0.271	Rubella IgM	2.490
RUB-2	0.191	Rubella IgM	1.230
RUB-4	0.063	Rubella IgM	2.340
RUB-7	0.090	Rubella IgM	2.340
RUB-8	0.063	Rubella IgM	1.290

RUB-12	0.159	Rubella IgM	1.090
RUB-19	0.085	Rubella IgM	1.240
RUB-20	0.143	Rubella IgM	1.830
HSV-1	0.287	HSV 1/2	3.43/2.77
HSV-2	0.180	HSV 1/2	1.44/1.33
HSV-3	0.233	HSV 1/2	0.91/0.78
HSV-4	0.600	HSV 1/2	1.99/1.88
HSV-5	0.962	HSV 1/2	1.72/2.71
HSV-6	0.770	HSV 1/2	1.99/0.46

^a Results of the various specimens using the respective DRG ELISA test system. For all ELISA test systems, a ratio of less than 0.900 is negative, and a ratio of greater than 1.10 is positive.

REFERENCES

1. Rapp CE, and Heweston JF: Infectious mononucleosis and the Epstein-Barr virus. *Am. J. Dis. Child.* 132:78,1978.
2. Biggar RJ, Henie W, Fleisher G, Bocker J, Lennette ET, and Henie G: Primary Epstein-Barr virus infections in African infants. I: Decline of maternal antibodies and time of infection. *Int. J. Cancer.* 22:239,1978.
3. Fry J: Infectious mononucleosis: Some new observations from a 15 year study. *J. Fam. Prac.* 10:1087,1980.
4. Lennette ET: Epstein-Barr virus. In: *Manual of Clinical Microbiology*, 4th edition. Lennette ET, Balows A. Hausler WJ, Shadomy HJ, eds. Washington DC, American Society for Microbiology, p. 326,1987.
5. Fleisher G, Henie W, Henie G. Lennette ET, and Biggar RJ: Primary infection with Epstein-Barr virus in infants in the United States: Clinical and Serological Observations. *J. Infect Dis.* 139:553,1979.
6. Merlin TL: Chronic mononucleosis: Pitfalls in the laboratory diagnosis. *Hum. Path.* 17:2,1986.
7. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS: Epstein-Barr virus replication in oropharyngeal epithelial cells. *New Eng. J. Med.* 310:1225,1984.
8. Chang RS, Lewis JP, Reynolds RD, Sullivan MJ, Neuman J: Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. *Ann. Intern. Med.* 88:34,1978.
9. Jones JF, Ray G, Minnich LL, Hicks MJ, Kibler R, Lucus DO: Evidence of active Epstein-Barr virus infection in patients with persistent, unexplained illness. Elevated anti-early antigen antibodies. *Ann. Intern. Med.* 102:1,1985.
10. Evans AS, Neiderman JC, Cenabre LC, West B, and Richards VA: A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody. *J. Infect. Dis.* 132:546,1975.
11. Henie W, Henie GE. and Horow'rtz CA: Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. *Hum. Path.* 5:551,1974.
12. Lennette ET. and Henie W: Epstein-Barr virus infections: Clinical and serological features. *Lab Management*, p. 23, June, 1987.
13. Reedman BM, and Klein G: Cellular localization of an Epstein-Barr virus (EBV) associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. *Int. J. Cancer* 11:499,1973.
14. Henie G. Henie W, and Horowitz CA: Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. *J. Infect. Dis.* 130:231,1974.

15. Horowitz CA, Henie W, Henie G, Rudnick H, and Lutts E; Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. *J. Infect. Dis.* 151:1150,1985.
16. Horowitz CA, Henie W, Henie G, and Schmrtz H: Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. *Am. J. Med.* 58:330. 1975.
17. Sumaya CV: Endogenous reactivation of Epstein-Barr virus infections. *J. Infect. Dis.* 135:374,1977.
18. Joncas J, Lapointe N, Gervais F, Leyritz M, and Wills A: Unusual prevalence of antibodies to Epstein-Barr virus early antigen in ataxiatelangiectasia. *Lancet* 1:1160,1977.
19. Akaboshi I, Jamamoto J, Katsuki T, and Matsuda I: Unique pattern of Epstein-Barr virus specific antibodies in recurrent parotitis. *Lancet* 2:1048.1983.
20. Larson PD, Bloomer LC, and Brag PF: Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. *Neurology* 35:435,1985.
21. Henie W, Ho H-C, Henie G, and Kwan HC: Antibodies to Epstein-Barr virus related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors, *J. Natl. Cancer Inst.* 51:361.1973.
22. Henie W, and Henie G: Epstein-Barr virus-specific serology in immunologically compromised individuals. *Cancer Res.* 41:4222,1981.
23. Fleisher G, and Bolognese R: Persistent Epstein-Barr virus infection and pregnancy. *J. Infect. Dis.* 147:982,1983.
24. Engvall E and Periman P: Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. *Immunochem.* 8:871-874.1971.
25. Engvall E and Periman P: Enzyme-linked immunosorbent assay, ELISA. III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen coated tubes. *J. Immunol.* 109:129-135,1972.
26. Voller A, Bartlett A, and Bidwell DE: Enzyme immunoassays with special reference to ELISA technique. *J. Clin. Pathol.* 31:507-520,1978.
27. Hopkins RF, Witmer TJ, Neubauer RH, and Rabin H: Detection of antibodies to Epstein-Barr virus antigens by enzyme-linked immunosorbent assay. *J. Infect. Dis.* 146:734-740,1982.
28. Procedures for the collection of diagnostic blood specimens by venipuncture. Second Edition; Approved Standard (1984). Published by National Committee for Clinical Laboratory Standards.
29. Procedures for the Handling and Processing of Blood Specimens. NCCLS Document H18-A, Vol. 10, No. 12, Approved Guideline. 1990.
30. Hallee TJ, Evans AS, Neiderman JC, Brooks CM and Boegtiy: Infectious mononucleosis at the United States Military Academy, a prospective study of a single class over four years. *Yale J. Biol. Med.* 47:182-192,1974.
31. Nickoskelainen J. and Hanninen P: Antibody response to Epstein-Barr virus in Infectious Mononucleosis. *Infect. & Immun.* 11:42-51,1975.
32. Roitt I: The immunoglobulin. In: Roitt I, *Essential Immunology*. 7th ed. Blackwell Scientific Publications, Oxford. 1991.
33. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational Exposure to Bloodborne Pathogens. Final Rule. *Fed. Register* 56:64175-64182.1991.

ABBREVIATED TEST PROCEDURE

1. Dilute Serum 1:21
2. Add diluted serum to microwell 100 uL/Well
3. —————→ Incubate 20 to 30 minutes.
4. Wash
5. Add Conjugate – 100 uL/Well
6. —————→ Incubate 20 to 30 minutes
7. Wash
8. Add TMB 100 uL/Well
9. —————→ Incubate 10 to 15 minutes
10. Add Stop Solution 50 uL/Well-Mix
11. READ